Quote | SonicShares Airlines, Hotels, Cruise Lines ETF (NYSE:TRYP)
Last: | $3.74 |
---|---|
Change Percent: | 3.31% |
Open: | $3.67 |
Close: | $3.74 |
High: | $3.75 |
Low: | $3.67 |
Volume: | 76,761 |
Last Trade Date Time: | 07/19/2022 04:40:57 am |
News | SonicShares Airlines, Hotels, Cruise Lines ETF (NYSE:TRYP)
KELOWNA, BC / ACCESSWIRE / March 12, 2024 / Tryp Therapeutics, Inc. (" Tryp " or the " Company ") ( CSE:TRYP)(OTCQB:TRYPF ) is pleased to announce that the Company's securityholders overwhelmingly approved the previously announced arrangement (the " Arrangement ") involving the Company and Exoph...
KELOWNA, BC / ACCESSWIRE / February 8, 2024 / Tryp Therapeutics, Inc. (" Tryp " or the " Company ") ( CSE:TRYP)(OTCQB:TRYPF ), a pioneering clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet m...
Message Board Posts | SonicShares Airlines, Hotels, Cruise Lines ETF (NYSE:TRYP)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
SonicShares Airlines, Hotels, Cruise Lines ETF Company Name:
TRYP Stock Symbol:
NYSE Market:
KELOWNA, BC / ACCESSWIRE / March 12, 2024 / Tryp Therapeutics, Inc. (" Tryp " or the " Company ") ( CSE:TRYP)(OTCQB:TRYPF ) is pleased to announce that the Company's securityholders overwhelmingly approved the previously announced arrangement (the " Arrangement ") involving the Company and Exoph...
KELOWNA, BC / ACCESSWIRE / February 8, 2024 / Tryp Therapeutics, Inc. (" Tryp " or the " Company ") ( CSE:TRYP)(OTCQB:TRYPF ), a pioneering clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet m...
KELOWNA, BC / ACCESSWIRE / January 26, 2024 / Tryp Therapeutics, Inc. (" Tryp " or the " Company ") ( CSE:TRYP )( OTCQB:TRYPF ), a pioneering clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet...